Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical compa
How this was made
The 30-second read
Why it matters
Regulatory clearance removes a major hurdle, enabling continued trial enrollment and data generation, which could improve valuation.
Market read
The news is a primary catalyst for ABUS and may influence related biotech stocks.
What to watch
Potential competition from other HBV therapies and the ongoing LNP patent litigation.
Background
Arbutus Biopharma (NASDAQ:ABUS) focuses on infectious diseases and is developing an oral PD‑L1 inhibitor for chronic hepatitis B.
Ticker impact
FDA lifted the clinical hold on ABUS's IND for oral PD‑L1 inhibitor AB‑101, allowing further US development.
upward pressure as investors price in resumed clinical progress
Regulatory clearance is a material catalyst for a clinical‑stage biotech; the news is fresh and not previously reported.
Market effects
May boost sentiment for HBV therapeutics and broader biotech sector.
US biotech stocks could see modest gains.
Limited to investors focused on clinical‑stage biotech.
Counterpoint
If the upcoming trial data disappoint, the lift may be priced in already.
Key entities
- companyArbutus Biopharma Corp
Clinical‑stage biotech developing AB‑101 for chronic HBV.
- regulatorFDA
U.S. Food and Drug Administration that lifted the clinical hold.
